Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 133

1.

Differential DNA methylation profiles of coding and non-coding genes define hippocampal sclerosis in human temporal lobe epilepsy.

Miller-Delaney SF, Bryan K, Das S, McKiernan RC, Bray IM, Reynolds JP, Gwinn R, Stallings RL, Henshall DC.

Brain. 2015 Mar;138(Pt 3):616-31. doi: 10.1093/brain/awu373. Epub 2014 Dec 30.

PMID:
25552301
2.

CASP8 SNP D302H (rs1045485) is associated with worse survival in MYCN-amplified neuroblastoma patients.

Rihani A, De Wilde B, Zeka F, Laureys G, Francotte N, Tonini GP, Coco S, Versteeg R, Noguera R, Schulte JH, Eggert A, Stallings RL, Speleman F, Vandesompele J, Van Maerken T.

PLoS One. 2014 Dec 11;9(12):e114696. doi: 10.1371/journal.pone.0114696. eCollection 2014.

3.

Robust selection of cancer survival signatures from high-throughput genomic data using two-fold subsampling.

Lee S, Rahnenführer J, Lang M, De Preter K, Mestdagh P, Koster J, Versteeg R, Stallings RL, Varesio L, Asgharzadeh S, Schulte JH, Fielitz K, Schwermer M, Morik K, Schramm A.

PLoS One. 2014 Oct 8;9(10):e108818. doi: 10.1371/journal.pone.0108818. eCollection 2014.

4.

MYCN repression of Lifeguard/FAIM2 enhances neuroblastoma aggressiveness.

Planells-Ferrer L, Urresti J, Soriano A, Reix S, Murphy DM, Ferreres JC, Borràs F, Gallego S, Stallings RL, Moubarak RS, Segura MF, Comella JX.

Cell Death Dis. 2014 Sep 4;5:e1401. doi: 10.1038/cddis.2014.356.

PMID:
25188511
5.

Modulation of chemotherapeutic drug resistance in neuroblastoma SK-N-AS cells by the neural apoptosis inhibitory protein and miR-520f.

Harvey H, Piskareva O, Creevey L, Alcock LC, Buckley PG, O'Sullivan MJ, Segura MF, Gallego S, Stallings RL, Bray IM.

Int J Cancer. 2015 Apr 1;136(7):1579-88. doi: 10.1002/ijc.29144. Epub 2014 Sep 2.

PMID:
25137037
6.

Lack of association between MDM2 promoter SNP309 and clinical outcome in patients with neuroblastoma.

Rihani A, Van Maerken T, De Wilde B, Zeka F, Laureys G, Norga K, Tonini GP, Coco S, Versteeg R, Noguera R, Schulte JH, Eggert A, Stallings RL, Speleman F, Vandesompele J.

Pediatr Blood Cancer. 2014 Oct;61(10):1867-70. doi: 10.1002/pbc.24927. Epub 2014 Jan 4.

PMID:
24391119
7.

Discovery and visualization of miRNA-mRNA functional modules within integrated data using bicluster analysis.

Bryan K, Terrile M, Bray IM, Domingo-Fernandéz R, Watters KM, Koster J, Versteeg R, Stallings RL.

Nucleic Acids Res. 2014 Feb;42(3):e17. doi: 10.1093/nar/gkt1318. Epub 2013 Dec 18.

8.

Metastasis suppressor microRNA-335 targets the formin family of actin nucleators.

Lynch J, Meehan MH, Crean J, Copeland J, Stallings RL, Bray IM.

PLoS One. 2013 Nov 5;8(11):e78428. doi: 10.1371/journal.pone.0078428. eCollection 2013.

9.

Investigating gene promoter methylation in a mouse model of status epilepticus.

Miller-Delaney SF, Das S, Stallings RL, Henshall DC.

Methods Mol Biol. 2013;1067:87-101. doi: 10.1007/978-1-62703-607-8_7.

PMID:
23975788
10.

Orchestrating osteogenic differentiation of mesenchymal stem cells--identification of placental growth factor as a mechanosensitive gene with a pro-osteogenic role.

McCoy RJ, Widaa A, Watters KM, Wuerstle M, Stallings RL, Duffy GP, O'Brien FJ.

Stem Cells. 2013 Nov;31(11):2420-31. doi: 10.1002/stem.1482.

11.

ERBB3 is a marker of a ganglioneuroblastoma/ganglioneuroma-like expression profile in neuroblastic tumours.

Wilzén A, Krona C, Sveinbjörnsson B, Kristiansson E, Dalevi D, Øra I, De Preter K, Stallings RL, Maris J, Versteeg R, Nilsson S, Kogner P, Abel F.

Mol Cancer. 2013 Jul 8;12(1):70. doi: 10.1186/1476-4598-12-70.

12.

Identification of circulating microRNAs in HNF1A-MODY carriers.

Bonner C, Nyhan KC, Bacon S, Kyithar MP, Schmid J, Concannon CG, Bray IM, Stallings RL, Prehn JH, Byrne MM.

Diabetologia. 2013 Aug;56(8):1743-51. doi: 10.1007/s00125-013-2939-4. Epub 2013 May 15.

PMID:
23674172
13.

Expressional alterations in functional ultra-conserved non-coding RNAs in response to all-trans retinoic acid--induced differentiation in neuroblastoma cells.

Watters KM, Bryan K, Foley NH, Meehan M, Stallings RL.

BMC Cancer. 2013 Apr 8;13:184. doi: 10.1186/1471-2407-13-184.

14.

MicroRNA-497 increases apoptosis in MYCN amplified neuroblastoma cells by targeting the key cell cycle regulator WEE1.

Creevey L, Ryan J, Harvey H, Bray IM, Meehan M, Khan AR, Stallings RL.

Mol Cancer. 2013 Mar 26;12:23. doi: 10.1186/1476-4598-12-23.

15.

Subcortical white matter abnormalities because of previously undescribed de-novo 14q12-q13.1 triplication.

Rea G, Stallings RL, Mullarkey M, McKinstry CS, McManus D, Morrison PJ.

Clin Dysmorphol. 2013 Apr;22(2):71-2. doi: 10.1097/MCD.0b013e32835f7465. No abstract available.

PMID:
23448906
16.

MiR-137 functions as a tumor suppressor in neuroblastoma by downregulating KDM1A.

Althoff K, Beckers A, Odersky A, Mestdagh P, Köster J, Bray IM, Bryan K, Vandesompele J, Speleman F, Stallings RL, Schramm A, Eggert A, Sprüssel A, Schulte JH.

Int J Cancer. 2013 Sep 1;133(5):1064-73. doi: 10.1002/ijc.28091. Epub 2013 Mar 7.

PMID:
23400681
17.

New insights into the genetics of neuroblastoma.

Sridhar S, Al-Moallem B, Kamal H, Terrile M, Stallings RL.

Mol Diagn Ther. 2013 Apr;17(2):63-9. doi: 10.1007/s40291-013-0019-6. Review.

PMID:
23329364
18.

The role of genetic and epigenetic alterations in neuroblastoma disease pathogenesis.

Domingo-Fernandez R, Watters K, Piskareva O, Stallings RL, Bray I.

Pediatr Surg Int. 2013 Feb;29(2):101-19. doi: 10.1007/s00383-012-3239-7. Epub 2012 Dec 29. Review.

19.

LIN28B induces neuroblastoma and enhances MYCN levels via let-7 suppression.

Molenaar JJ, Domingo-Fernández R, Ebus ME, Lindner S, Koster J, Drabek K, Mestdagh P, van Sluis P, Valentijn LJ, van Nes J, Broekmans M, Haneveld F, Volckmann R, Bray I, Heukamp L, Sprüssel A, Thor T, Kieckbusch K, Klein-Hitpass L, Fischer M, Vandesompele J, Schramm A, van Noesel MM, Varesio L, Speleman F, Eggert A, Stallings RL, Caron HN, Versteeg R, Schulte JH.

Nat Genet. 2012 Nov;44(11):1199-206. doi: 10.1038/ng.2436. Epub 2012 Oct 7.

PMID:
23042116
20.

Genome-wide promoter methylation analysis in neuroblastoma identifies prognostic methylation biomarkers.

Decock A, Ongenaert M, Hoebeeck J, De Preter K, Van Peer G, Van Criekinge W, Ladenstein R, Schulte JH, Noguera R, Stallings RL, Van Damme A, Laureys G, Vermeulen J, Van Maerken T, Speleman F, Vandesompele J.

Genome Biol. 2012 Oct 3;13(10):R95. doi: 10.1186/gb-2012-13-10-r95.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk